|
In vitro
|
PARP1 imaging35
|
AZD2281-TCO/Tz-Texas Red |
iEDDA |
| PARP1 target identification study36
|
AZD2281-TCO/Tz-cleavable linker-biotin |
iEDDA |
| Tubulin protein imaging37
|
Taxol-TCO/Tz-BODIPY FL |
iEDDA |
| Polo-like kinase 1 protein imaging38
|
BI2536-TCO/Tz-Texas Red |
iEDDA |
| Aurora kinase A protein imaging39
|
MLN8054-TCO/Tz-CFDA, Tz-Texas Red |
iEDDA |
| MET protein imaging40
|
PF04217903-TCO/Tz-CFDA |
iEDDA |
| Foretinib-TCO/Tz-CFDA |
iEDDA |
| Imaging binding targets of drug molecules41
|
Dasatinib-TCO/Tz-CFDA |
iEDDA |
| BTK protein imaging42
|
Ibrutinib-TCO/Tz-Cy5 |
iEDDA, SPACC |
| Ibrutinib-N3/DBCO-Cy5 |
| Drug imaging43
|
JQ1-TCO/Tz-Cy5 |
iEDDA |
| Visualization of PTM modification44
|
NAD+-DBCO/N3-Cy3, N3-Cy5 |
SPACC |
| NAD+-methyl cyclopropene/Tz-Cy3 |
iEDDA |
| Site-specific oligonucleotide labelling45–47
|
RNA-norbornene/Tz-Oregon Green 488 |
iEDDA |
| RNA-methyl cyclopropene/Tz-Oregon Green 488 |
| DNA-Tz/BCN-rhodamine |
| DNA-methyl cyclopropene/Tz-BODIPY |
| Site-specific protein labelling48
|
l-Lysine-TCO/Tz-Cy5 |
iEDDA |
| No-wash STED imaging49
|
Phalloidin-BCN/Tz-Cy3 |
iEDDA |
|
In vivo
|
Zebrafish embryo growth imaging24
|
N-Acetylgalactosamine (GalNAc)/difluorinated cyclooctyne (DIFO)-Alexa Fluor dye |
SPACC |
| Glycan imaging by intraperitoneal injection50
|
Tetraacetylated N-azidoacetyl-d-mannosamine (Ac4ManNAz)/DIFO-FLAG peptide conjugate |
SPACC |
| Brain glycan imaging51
|
Liposomes loading 9-azido sialic acid/DBCO-Cy5.5 |
SPACC |
| Tumor glycan imaging by SPECT52
|
Anti-TAG72 antibody CC49-TCO/Tz-111In |
SPACC |
| Tumor glycan imaging by MR53
|
Ac4GalNAz/TMDIBO-Lys-Gd (tetramethoxydibenzocyclooctyne-lysine-gadolinium) |
SPACC |
| Tumor VEGF (vascular endothelial growth factor receptor 2) imaging by ultrasound54
|
Antivascular endothelial growth factor receptor 2 antibody (TCO-antiVEGFR2)/Tz-modified microbubbles |
iEDDA |
| Acute thrombus imaging by ultrasound55
|
AntiCD62p-TCO/Tz-modified microbubbles |
iEDDA |
| Tumor-targeted liposomes for drug delivery25
|
Ac4ManNAz/DBCO-modified liposome |
SPACC |
| Tumor-targeted photosensitizer delivery27
|
Ac4ManNAz-loading chitosan nanoparticles/DBCO-modified chitosan nanoparticles |
SPACC |
| Tumor-targeted doxorubicin delivery56
|
Peptide-modified Ac4ManNAz/DBCO-modified doxorubicin |
SPACC |
| Upconversion nanoparticle-based photodynamic therapy57
|
Upconversion NP modified with Tz groups/norborane (NB)-conjugated rose bengal (RB) |
iEDDA |
| Endothelial progenitor cell therapy for myocardiac infarction58
|
Azide-modified CD34 antibody/DBCO-modified CD41 antibody |
SPACC |
|
Ex vivo
|
Glycoproteomic analysis of intact and hypertrophy hearts59
|
Ac4ManNAz/DBCO-Fluor 488 |
SPACC |
| Analysis of microvesicles from the blood of glioblastomas patients60
|
Antibody-modified TCO/Tz-modified magnetic nanoparticles |
iEDDA |
| Amplification of signal for diagnosis purpose61
|
Antibody-modified TCO/Tz-modified magneto-fluorescent nanoparticles |
iEDDA |
| Study of protein dynamics in the neuronal system62
|
Azidohomoalanine/DIFO-biotin |
SPACC |
| Study of the conformational change of protein by FRET63
|
Unnatural amino acid containing tetrazine or norbornene/BODIPY-FL tetrazine or BODIPY-TMR-X bicyclononyne |
iEDDA, SPACC |
| Nucleotide ligation for the CRISPR Cas9 system64
|
RNAs modified with alkyne or DBCO/RNAs modified with azide |
CuAAC, SPACC |
